On Monday, Morgan Stanley initiated coverage on Compass Pathways (NASDAQ:CMPS), a company specializing in psychedelic therapies, with an Overweight rating and a price target of $30.00. The firm views the current valuation as an attractive entry point, anticipating a year filled with significant catalysts.
The $30 price target is derived from a discounted cash flow (DCF) analysis, which attributes value to the company’s COMP360 product for treatment-resistant depression (TRD) with a 65% probability of success. Morgan Stanley estimates that COMP360 could achieve over $1 billion in peak risk-adjusted sales in the United States for TRD.
Additionally, the potential treatment for post-traumatic stress disorder (PTSD) is seen as an upside driver, with Phase II data expected in the spring. This opportunity is currently considered in Morgan Stanley’s bull case scenario.
Compass Pathways is recognized as an intriguing and cost-effective option within the burgeoning psychedelics sector. The market is expected to grow significantly in the near future, with key developments anticipated from Compass Pathways and other industry participants in 2024 and 2025.
However, the company does face certain risks. These include possible delays in the Phase III TRD program, adverse regulatory developments affecting psychedelic therapies, a Phase III TRD profile that may not align with investor expectations, and the potential for significant adverse events (AEs) in the forthcoming Phase II PTSD data set.
InvestingPro Insights
Morgan Stanley’s optimistic outlook on Compass Pathways (NASDAQ:CMPS) is intriguing, especially considering the company’s current financial and operational metrics. According to InvestingPro data, Compass Pathways holds a market cap of $568.61 million and has exhibited significant price volatility, with a 1-month price total return of -27.53%. This underscores the firm’s point about the attractive valuation at the current level.
InvestingPro Tips highlight that while Compass Pathways maintains more cash than debt, which is a positive sign of liquidity, the company is also experiencing a rapid cash burn and has not been profitable over the last twelve months. Analysts are not expecting profitability this year, which aligns with the company’s P/E ratio of -3.59, reflecting investor sentiment on future earnings.
For investors considering a deeper dive into Compass Pathways, there are 9 additional InvestingPro Tips available, offering a comprehensive analysis of the company’s financial health and stock performance. These can be accessed at https://www.investing.com/pro/CMPS. To enhance your investing strategy with these insights, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
feed from www.investing.com